<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04947371</url>
  </required_header>
  <id_info>
    <org_study_id>HCC-ANO-ADJ</org_study_id>
    <nct_id>NCT04947371</nct_id>
  </id_info>
  <brief_title>Adjuvant Therapy With Anlotinib for HCC</brief_title>
  <official_title>Adjuvant Therapy With Anlotinib Hydrochloride for Patients With Hepatocellular Carcinoma Who Underwent Curative Resection: a Single Arm Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with high risk of disease recurrence after curative resection for hepatocellular&#xD;
      carcinoma (HCC) deserve active intervention. However, there's limited treatment choice for&#xD;
      these patients. Anlotinib hydrochloride, a multitarget tyrosine kinase inhibitor for both&#xD;
      tumor angiogenesis and proliferative signaling in cancer cells, is approved in China for the&#xD;
      3rd line treatment of advanced non-small cell lung cancer. In the current study, we are to&#xD;
      evaluate the safety and effects of adjuvant anlotinib therapy for the patients who underwent&#xD;
      curative resection for HCC with high risk of tumor recurrence, which is defined by Shanghai&#xD;
      Score (Sun, et al. Chin Med J (Engl) 2017).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with high risk of disease recurrence after curative resection for hepatocellular&#xD;
      carcinoma (HCC) deserve active intervention. However, there's limited treatment choice for&#xD;
      these patients. Anlotinib hydrochloride, a multitarget tyrosine kinase inhibitor for both&#xD;
      tumor angiogenesis and proliferative signaling in cancer cells, is approved in China for the&#xD;
      3rd line treatment of advanced non-small cell lung cancer. In the current study, we are to&#xD;
      evaluate the safety and effects of adjuvant anlotinib therapy for the patients who underwent&#xD;
      curative resection for HCC with high risk of tumor recurrence, which is defined by Shanghai&#xD;
      Score (Sun, et al. Chin Med J (Engl) 2017).&#xD;
&#xD;
      The primary outcome of this study is treatment safety, and the secondary outcome is&#xD;
      recurrence-free survival and overall survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The standard of care of adjuvant therapy for liver cancer was changed.&#xD;
  </why_stopped>
  <start_date type="Actual">December 15, 2018</start_date>
  <completion_date type="Actual">March 30, 2019</completion_date>
  <primary_completion_date type="Actual">March 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events rate</measure>
    <time_frame>12 months</time_frame>
    <description>The rates of severity and seriousness of the adverse events. Adverse events are graded according to the NCI-CTCAE (Version 5.0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>24 months</time_frame>
    <description>From the date of liver surgery to the date of diagnosis of tumor recurrence or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
    <description>From the date of liver surgery to the date of death from any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Anlotinib Hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral anlotinib 12 mg/d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib Hydrochloride</intervention_name>
    <description>Oral anlotinib hydrochloride 12 mg/d</description>
    <arm_group_label>Anlotinib Hydrochloride</arm_group_label>
    <other_name>AL3818</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged from 18-75 years.&#xD;
&#xD;
          -  HCC diagnosis was confirmed by pathological examination and those who did not receive&#xD;
             anti-tumor treatment (anti-tumor treatment including but not limited to: local&#xD;
             ablation therapy, TACE, radiation therapy, chemotherapy, targeted drug therapy,&#xD;
             immunotherapy, and etc.)&#xD;
&#xD;
          -  Underwent curative resection for HCC with high risk of tumor recurrence, which was&#xD;
             defined by Shanghai Score ≥ 4.922 (Sun, et al. Chin Med J (Engl) 2017)&#xD;
&#xD;
          -  Child-Pugh class: A or B7&#xD;
&#xD;
          -  The ECOG Performance Status: 0-1 points&#xD;
&#xD;
          -  The expected survival time ≥ 6 months&#xD;
&#xD;
          -  No disease recurrence 4-6 weeks after surgery as evaluated by abdominal&#xD;
             contrast-enhanced CT/MRI and chest CT.&#xD;
&#xD;
          -  Adequate organs function&#xD;
&#xD;
          -  Complete blood counting HB ≥ 90 g/L ANC ≥ 1.5×10^9 /L PLT ≥ 75×10^9/L&#xD;
&#xD;
          -  Blood biochemistry ALB ≥ 28 g/L ALT and AST&lt; 5×ULN TBIL ≤ 2×ULN Serum creatinine ≤&#xD;
             1×ULN&#xD;
&#xD;
          -  Women of childbearing age must have pregnancy tests within 7 days prior to admission,&#xD;
             and the results are negative and are willing to use appropriate methods of&#xD;
             contraception at 8 weeks after the trial and at the end of the trial. For men,&#xD;
             surgical sterilization should be applied, or consent to use appropriate methods of&#xD;
             contraception 8 weeks after the trial and at the end of the trial.&#xD;
&#xD;
          -  Subjects voluntarily participated in the study, signed informed consent, good&#xD;
             compliance in drug therapy and followed up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cholangiocarcinoma, the combination of cholangiocarcinoma of HCC, or fibrolamellar HCC&#xD;
             diagnosed by pathology examination.&#xD;
&#xD;
          -  Past or current diagnosed with other malignancy, except skin basal cell carcinoma and&#xD;
             cervical carcinoma in situ.&#xD;
&#xD;
          -  Those treated with liver or other organ transplantation or willing to undergo liver&#xD;
             transplantation.&#xD;
&#xD;
          -  The conditions not suitable for oral medications, including difficulty swallowing,&#xD;
             chronic diarrhoea, or bowel obstruction.&#xD;
&#xD;
          -  Vascular events within 6 months, including stroke and transient ischemic attack&#xD;
&#xD;
             , deep venous thrombosis or pulmonary artery embolism.&#xD;
&#xD;
          -  Alimentary tract hemorrhage or high risk of alimentary tract hemorrhage due to&#xD;
             esophageal varices, active ulcerative lesions or ulcerative colitis; or fecal occult&#xD;
             blood test ≥ ++, or for those with fecal occult blood test (+), gastroscopy is&#xD;
             required.&#xD;
&#xD;
          -  Abnormal coagulation function (international normalized ratio &gt; 2, prothrombin time &gt;&#xD;
             16 s, thrombin time &gt;21s, activated partial thromboplastin time &gt; 21 s, or fibrinogen&#xD;
             &lt; 2 g/L); or other conditions with bleeding tendency or undergoing thrombolysis or&#xD;
             anticoagulant therapy.&#xD;
&#xD;
          -  Other severe or uncontrolled comorbidities:&#xD;
&#xD;
          -  hypertension and the blood pressure was not well managed by medications (systolic&#xD;
             pressure ≥ 150 mmHg or diastolic pressure ≥ 90 mmHg); level 2 or higher myocardial&#xD;
             ischemia or myocardial infarction, uncontrolled arrhythmia (including QTc interval ≥&#xD;
             480 ms); level 1 heart dysfunction; or LVEF &lt; 50%.&#xD;
&#xD;
          -  active or uncontrolled infection.&#xD;
&#xD;
          -  uncontrolled diabetes (fasting blood glucose &gt; 10 mmol/L).&#xD;
&#xD;
          -  Urinary protein ≥ ++ or 24 hours urine protein &gt; 1 g.&#xD;
&#xD;
          -  Unhealed wounds, ulcer, or bone fracture.&#xD;
&#xD;
          -  Those with mental illness or a history of psychotropic substance abuse; HIV infection.&#xD;
&#xD;
          -  Other conditions that the investigators considered that not suitable for trial&#xD;
             inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jia Fan, MD&amp;PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hui-Chuan Sun, MD&amp;PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, Yu H, Zhao Y, Chen W, Luo Y, Wu L, Wang X, Pirker R, Nan K, Jin F, Dong J, Li B, Sun Y. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2018 Nov 1;4(11):1569-1575. doi: 10.1001/jamaoncol.2018.3039. Erratum in: JAMA Oncol. 2018 Nov 1;4(11):1625.</citation>
    <PMID>30098152</PMID>
  </reference>
  <reference>
    <citation>Sun HC, Xie L, Yang XR, Li W, Yu J, Zhu XD, Xia Y, Zhang T, Xu Y, Hu B, Du LP, Zeng LY, Ouyang J, Zhang W, Song TQ, Li Q, Shi YH, Zhou J, Qiu SJ, Liu Q, Li YX, Tang ZY, Shyr Y, Shen F, Fan J. Shanghai Score: A Prognostic and Adjuvant Treatment-evaluating System Constructed for Chinese Patients with Hepatocellular Carcinoma after Curative Resection. Chin Med J (Engl). 2017 Nov 20;130(22):2650-2660. doi: 10.4103/0366-6999.218019. Erratum in: Chin Med J (Engl). 2017 Dec 20;130(24):3020.</citation>
    <PMID>29133751</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2021</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Hui-Chuan Sun</investigator_full_name>
    <investigator_title>Professor of Surgery</investigator_title>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>anlotinib</keyword>
  <keyword>adjuvant</keyword>
  <keyword>surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

